Summary: Free radical-induced oxidative damage reactions, and membrane lipid peroxidation (LP), in particular, are among the best validated secondary injury mechanisms in preclinical traumatic brain injury (TBI) models. In addition to the disruption of the membrane phospholipid architecture, LP results in the formation of cytotoxic aldehyde-containing products that bind to cellular proteins and impair their normal functions. This article reviews the progress of the past three decades in regard to the preclinical discovery and attempted clinical development of antioxidant drugs designed to inhibit free radical-induced LP and its neurotoxic consequences via different mechanisms including the O 2 ⅐Ϫ scavenger superoxide dismutase and the lipid peroxidation inhibitor tirilazad. In addition, various other antioxidant agents that have been shown to have efficacy in preclinical TBI models are briefly presented, such as the LP inhibitors U83836E, resveratrol, curcumin, OPC-14177, and lipoic acid; the iron chelator deferoxamine and the nitroxidecontaining antioxidants, such as ␣-phenyl-tert-butyl nitrone and tempol. A relatively new antioxidant mechanistic strategy for acute TBI is aimed at the scavenging of aldehydic LP byproducts that are highly neurotoxic with "carbonyl scavenging" compounds. Finally, it is proposed that the most effective approach to interrupt posttraumatic oxidative brain damage after TBI might involve the combined treatment with mechanistically complementary antioxidants that simultaneously scavenge LP-initiating free radicals, inhibit LP propagation, and lastly remove neurotoxic LP byproducts.
INTRODUCTION
At present, there are no Food and Drug Administration pharmacological therapies that have been approved for the acute treatment of traumatic brain injury (TBI) patients that are conclusively proven to mitigate the often devastating neurological effects of their injuries. Nevertheless, the possibility of an effective treatment is based on the fact that even though some of the neural injury is due to the primary mechanical events (i.e., shearing of nerve cells and blood vessels), the majority of posttraumatic neurodegeneration is due to a pathochemical and pathophysiological cascade of secondary events occurring during the first minutes, hours, and days after the injury that exacerbates the damaging effects of the primary injury. Arguably, one of the most validated "secondary injury" mechanisms revealed in experimental TBI studies involves oxygen radical-induced oxidative damage to lipids, proteins, and nucleic acids. This review briefly outlines the key sources of reactive oxygen species (ROS), including their derived highly reactive free radicals, the mechanisms associated with their neural damage and the past, present, and future of pharmacological antioxidants that should be able to produce a clinically demonstrable neuroprotective effect, if properly applied.
OXIDATIVE DAMAGE IN TBI

Superoxide radical
The first body of work showing a role of oxygen radicals in acute TBI pathophysiology was conducted by Kontos and Povlishock 1 and Kontos and Wei 2 who demonstrated an almost immediate post-injury increase in brain microvascular superoxide radical (O 2 ⅐Ϫ ) production associated with compromise of autoregulatory function in fluid percussion TBI models. These early investigators also demonstrated that scavengers of O 2 ⅐Ϫ decrease the post-traumatic superoxide levels and protect against the loss of microvascular autoregulatory competency. Within the injured nervous system, a number of possible sources of O 2 ⅐Ϫ may be operative during the first minutes and hours after injury including: the arachidonic acid cascade (i.e., prostaglandin synthase and 5-lipoxygenase activity), enzymatic or autoxidation of biogenic amine neurotransmitters (e.g., dopamine, norepinephrine, 5-hydroxytryptamine), "mitochondrial leak," xanthine oxidase activity, and the oxidation of extravasated hemoglobin. Activated microglia and infiltrating neutrophils and macrophages provide additional sources of O 2 ⅐Ϫ at later time points. Superoxide, which is formed by the single electron reduction of oxygen, may act as either an oxidant or reductant. Although O 2 ⅐Ϫ itself is reactive, its direct reactivity toward biological substrates in aqueous environments is relatively weak. Moreover 
Iron and hydroxyl radical
The CNS is an extremely rich source of iron and its regional distribution varies in parallel with the sensitivity of various regions to oxidative damage. 4 Under normal circumstances, low molecular weight forms of redoxactive iron are maintained at extremely low levels. In plasma, the iron transport protein transferrin tightly binds iron in the Fe ϩϩϩ form. Intracellularly, Fe ϩϩϩ is sequestered by the iron storage protein ferritin. Although both ferritin and transferrin have a very high affinity for iron at neutral pH and effectively maintain iron in a noncatalytic state, 3 both proteins readily give up their iron at pH values of 6.0 or less, which is a level of acidosis that has been shown to be reached in the injured brain. Once iron is released from ferritin or transferring, it can actively catalyze oxygen radical reactions. Therefore, within the traumatized brain, where pH in injured areas is typically lowered, conditions are favorable for the potential release of iron from storage proteins. 3 In the case of ferritin, its iron can also be released by reductive mobilization by O 2
⅐Ϫ
. A second source of catalytically active iron is hemoglobin. Hemorrhage resulting from mechanical trauma provides an obvious source of hemoglobin. Although hemoglobin itself has been reported to stimulate oxygen radical reactions, it is more likely that iron released from hemoglobin is responsible for hemoglobin-mediated oxidative damage. 5, 6 Iron is released from hemoglobin by either H 2 O 2 or by lipid hydroperoxides (LOOH; see as follows), and this release is further enhanced as the pH falls to 6.5 or below. Therefore, hemoglobin may catalyze oxygen radical formation and LP either directly or through the release of iron by H 2 O 2 , LOOH and/or acidic pH.
Free iron or iron chelates participate in free radical reactions at two levels. Using the salicylate trapping method, a rise in brain ⅐OH levels has also been documented in a mouse diffuse and rat focal TBI models by the senior author 7, 8 and others. 8 -10 As with the previously discussed work of Kontos and Povlishock 1 and Kontos and Wei, 2 the cerebral microvasculature appears to be the initial source of post-traumatic ⅐OH production.
Chemistry of lipid peroxidation and target mechanisms for its pharmacological inhibition
The most studied mechanism of oxidative damage in models of TBI concerns free radical-induced lipid peroxidation (LP). The process of LP is presented in FIG. 1 in the context of the ⅐OH-induced peroxidation of the LP-susceptible arachidonic acid (AA), which is highly enriched in brain cell membranes. "Initiation" of LP occurs when a radical species such as ⅐OH reacts with and removes an allylic carbon (carbon surrounded by adjacent double bonds) and extracts a hydrogen and its single electron from AA (AA ϩ R⅐ ¡ AA⅐ ϩ RH). In the process, the initiating radical is quenched by receipt of an electron (hydrogen) from the polyunsaturated AA. This, however, converts the AA into a lipid or "alkyl" radical (AA⅐). This sets the stage for a series of "propagation" reactions, which begins when the alkyl radical takes on a mole of oxygen creating a lipid peroxyl radical (AA-OO⅐; AA⅐ ϩ O 2 ¡ AA-OO⅐). The peroxyl radical then reacts with a neighboring AA within the membrane and steals its electron forming a lipid hydroperoxide (AA-OOH) and a second alkyl radical (AA⅐; AA-OO⅐ ϩ AA ¡ AA-OOH ϩ AA⅐).
Once 
Ultimately, the LP process leads to "fragmentation" or "scission" reactions in which the peroxidized AA breaks down to give rise to the neurotoxic aldehydes 4-hydroxynonenal (4-HNE) or 2-propenal (acrolein). 
Other forms of oxidative damage
The central nervous system is exquisitely sensitive to LP because of its high content of peroxidation-susceptible lipids, such as AA, linoleic acid, linolenic acid, and docosahexaenoic acid and the high levels of iron. Although LP disrupts the normal phospholipid architecture of cellular and subcellular organellar membranes, endproducts of LP, most notably 4-HNE and acrolein, can bind to proteins, modifying their structure and compromising function. However, primary radical-mediated oxidative damage can also occur in proteins. For instance, iron-catalyzed, ⅐OH mechanisms can target certain basic amino acids (e.g., lysine, arginine, histidine) leading to the formation of "protein carbonyl" moieties. Another form of protein oxidative damage involves the oxidation of cysteine sulfhydryl groups, which can lead to the formation of abnormal disulfide bridges.
Nucleic acids, both DNA and RNA, are also susceptible to oxidative modification by inorganic and organic (i.e., lipid) radicals. In addition to potentially compromising DNA replication, transcription, and mRNA translation, DNA oxidative damage also triggers DNA repair mechanisms that can greatly stress cellular function and survival. One such mechanism concerns the activation of poly ADP ribose polymerase whose action can lead to severe depletion of cellular stores of ATP. In addition, DNA-protein cross-linking can occur (e.g., thymine-tyrosine). 3 However, compared with the numerous studies that have documented post-traumatic LP and protein oxidative damage in TBI models, very little examination of nucleic acid oxidation has occurred.
Peroxynitrite
Nearly 20 years ago, Beckman 11 introduced the theory that the principal ROS involved in producing tissue injury in a variety of neurological disorders is the "reactive nitrogen species" peroxynitrite (PN; ONOO Ϫ ), which is formed by the combination of nitric oxide synthase (NOS)-generated ⅐NO radical and O 2
Since that time, the biochemistry of PN has been in large part defined. PN-mediated oxidative damage is actually caused by PN decomposition products that possess potent-free radical characteristics. These are formed in one of two ways. The first involves the protonation of PN to form peroxynitrous acid (ONOOH), which can undergo homolytic decomposition to form the highly reactive nitrogen dioxide radical (⅐NO 2 ) and OH; (ONOOH ¡ ⅐NO 2 ϩ ⅐OH). Perhaps more important physiologically, PN will react with carbon dioxide (CO 2 ) to form nitrosoperoxocarbonate (ONOOCO 2 ), which can decompose into ⅐NO 2 and carbonate radical (⅐CO 3 ); (ONOOCO 2 ¡ ⅐NO 2 ϩ ⅐CO 3 ).
Each of the PN-derived radicals (⅐OH, ⅐NO 2 and ⅐CO 3 )
can initiate LP cellular damage by abstraction of an electron from a hydrogen atom bound to an allylic carbon in polyunsaturated fatty acids or cause protein carbonylation by reaction with susceptible amino acids (e.g., lysine, cysteine, arginine). In addition, ⅐NO 2 can nitrate the third position of tyrosine residues in proteins; 3-NT is a specific footprint of PN-induced cellular damage. Peroxynitrite-mediated protein nitration can involve the initial oxidation of a tyrosine moiety by a lipid peroxyl or alkoxyl radical, followed by nitration by ⅐NO 2 .
The implication of PN in post-TBI pathophysiology is derived from four lines of evidence. First of all, all three NOS isoforms (endothelial, neuronal, and inducible) are known to be up regulated during the first 24 h after TBI in rodents. [12] [13] [14] Second, several laboratories have shown that the acute treatment of injured mice or rats with NOS inhibitors can exert a neuroprotective effect and/or improve neurological recovery. [15] [16] [17] [18] [19] [20] [21] [22] Third, biochemical footprints of PN-mediated damage have been documented in rodent TBI paradigms, including an increase in 3-NT levels 15, 21 and ADP ribosylation (evidence of poly ADP ribose polymerase activation). Fourth, the notion that these markers of PN-mediated damage are pathophysiologically important is supported by the finding that the NOS inhibitor L-NAME can lessen the accumulation of 3-NT in in- jured brains 15, 21 at the same doses that improve neurological recovery. 23 
MECHANISMS FOR PHARMACOLOGICAL INHIBITION OF OXIDATIVE DAMAGE IN TBI
Based on this outline of the steps involved in oxygen radical-induced oxidative damage, and LP in particular, a number of potential mechanisms for its inhibition are apparent, which fall into three categories. The first category includes compounds that inhibit the initiation of LP and other forms of oxidative damage by preventing the formation of ROS or reactive nitrogen species. For instance, NOS inhibitors, as previously discussed, exert an indirect antioxidant effect by limiting ⅐NO production and thus PN formation. However, they also have the potential to interfere with the physiological roles that ⅐NO is responsible for including antioxidant effects, which are due its important role as a scavenger of lipid peroxyl radicals (e.g., AAOO⅐ ϩ ⅐NO ¡AAOONO).
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Another approach to blocking post-traumatic radical formation is the inhibition of the enzymatic (e.g., cyclooxygenase, 5-lipoxygenases) AA cascade during which the formation of O 2 ⅐Ϫ is produced as a byproduct of prostanoid and leukotriene synthesis. Kontos and Wei, 2 Kontos, 25 and Hall and coworkers 26, 27 have shown that cyclooxygenase inhibiting nonsteroidal anti-inflammatory agents (e.g., indomethacin, ibuprofen) are vasoprotective and neuroprotective in TBI models.
A second indirect LP inhibitory approach involves chemically scavenging the radical species (e.g., O 2 ⅐Ϫ , ⅐OH, ⅐NO 2 , ⅐CO 3 ) before they have a chance to steal an electron from a polyunsaturated fatty acid and thus initiate LP. The use of pharmacologically-administered SOD represents an example of this strategy. Another example concerns the use of the nitroxide antioxidant tempol, which has been shown to catalytically scavenge the PN-derived free radicals ⅐NO 2 and ⅐CO 3 . 28 In either case, a general limitation to these first two approaches is that they would be expected to have a short therapeutic window and would have to be administered rapidly to have a chance to interfere with the initial post-traumatic "burst" of free radical production that has been documented in TBI models. 2, 29 Although it is believed that ROS, including PN production, persists several hours after injury, the major portion is an early event that peaks in the first 60 minutes after injury, making it clinically impractical to pharmacologically inhibit, unless the antioxidant compound is already "on board" when the injury occurs, or it is available for administration immediately thereafter.
In contrast, indirect-acting antioxidant mechanisms, the third category, involves stopping the "chain reaction" propagation of LP once it has begun. The most demonstrated way to accomplish this is by scavenging lipid peroxyl (LOO⅐) or alkoxyl (LO⅐) radicals. The endogenous scavenger of these lipid radicals is alpha tocopherol or vitamin (Vit) E, which can donate an electron from its phenolic hydroxyl moiety to quench LOO⅐. However, the scavenging process is stoichiometric (1 Vit E can only quench 1 LOO⅐), and in the process, Vit E loses its antioxidant efficacy and becomes Vit E radical (LOO⅐ ϩ Vit E ¡ LOOH ϩ Vit E⅐). Although Vit E⅐ is relatively unreactive (i.e., harmless), it also can not scavenge another LOO⅐ until it is reduced back to its active form by receiving an electron from other endogenous antioxidant reducing agents, such as ascorbic acid (Vit C) or glutathione. Although this tripartite LOO⅐ antioxidant defense system (Vit E, Vit C, glutathione) works fairly effectively in the absence of a major oxidative stress, numerous studies have shown that each of these antioxidants is rapidly consumed during the early minutes and hours after TBI. Thus, it has been recognized for a long time that more effective pharmacological LOO⅐ and LO⅐ scavengers are needed. Furthermore, it is expected that compounds that could interrupt the LP process after it has begun would be able to exert a more practical neuroprotective effect (i.e., possess longer antioxidant therapeutic window).
A second approach to inhibiting the propagation of LP reactions is to chelate free iron, either ferrous (Fe 
NEUROPROTECTIVE EFFECTS OF PHARMACOLOGICAL ANTIOXIDANTS TBI clinical trial results with polyethylene glycol-conjugated-SOD, tirilazad, and dexanabinol
During the past 25 years, there has been an intense effort to discover and develop pharmacological agents for acute treatment of TBI. This has included multiple compounds that possess free radical scavenging/antioxidant properties, including polyethylene glycol-conjugated superoxide dismutase (PEG-SOD), the LP inhibitor tirilazad, 30 -32 and more recently the mixed glutamate antagonist/antioxidant compound dexanabinol. 33 However, each of these trials was a therapeutic failure in that no overall benefit has been documented in moderate and severe TBI patient populations, which was the primary goal in each case. These failures can be attributed to several factors. Perhaps most importantly, the preclinical assessment of compounds destined for acute TBI trials has often been woefully inadequate in regard to the definition of neuroprotective dose-response relationships, pharmacokinetic-pharmacodynamic correlations, therapeutic window, and optimum dosing regimen and treatment duration. However, a number of other issues related to the design of the clinical trials are also believed to be involved. 32 The following sections briefly review the TBI histories of PEG-SOD and tirilazad. Dexanabinol (HU211) is not discussed further because it is a mixed glutamate antagonist/antioxidant compound that was studied very little in preclinical TBI paradigms prior to being the subject of clinical development for that indication.
PEG-SOD
As mentioned earlier, the earliest studies of free radical scavenging compounds in TBI models were carried out with Cu/Zn SOD based on the work of Kontos ⅐Ϫ generated as a byproduct of the arachidonic acid cascade, which is massively activated during the first minutes and hours after TBI. Their work showed that administration of SOD prevented the posttraumatic microvascular dysfunction. This led to clinical trials in which the more metabolically stable polyethylene glycol (PEG)-conjugated SOD was examined in moderate and severe TBI patients when administered within the first 8 h after injury. Although an initial small phase II study showed a positive trend, subsequent multicenter phase III studies failed to show a significant benefit in terms of increased survival or improved neurological outcomes. 34 Although many explanations for these negative results may be postulated, one reason may be that a large protein like SOD is unlikely to have much brain penetrability and therefore its radical scavenging effects may be limited to the microvasculature. A second reason may be that attempting to scavenge the shortlived inorganic radical O 2 ⅐Ϫ may be associated with a very short therapeutic window, as previously suggested. Indeed, the time course of measurable post-traumatic ⅐OH formation in the injured rodent brain has been shown to largely run its course by the end of the first hour after TBI.
9,29 A more rational strategy would be to inhibit the LP that is triggered by the initial burst of inorganic radicals. A comparison of the time course of LP with that of post-traumatic ⅐OH shows that LP reactions continue to build beyond the first post-traumatic hour 9 and may continue for 3 to 4 days. 35 Despite the failure of PEG-SOD in human TBI, experimental studies have shown that transgenic mice that over-express Cu/Zn SOD are significantly protected against post-TBI pathophysiology and neurodegeneration. 36 -40 This fully supports the importance of post-traumatic O 2 ⅐Ϫ in post-traumatic secondary injury, despite the fact that targeting this primordial radical is probably not the best antioxidant strategy for acute CNS injury compared with trying to stop the downstream LP process that is initiated by the early increases in O 2 ⅐Ϫ , ⅐OH, ⅐NO 2 , and ⅐CO 3 .
Tirilazad
Consistent with that rationale, the 21-aminosteroid LP inhibitor tirilazad (aka U74006F) was discovered, which inhibits free radical-induced LP by a combination of LOO⅐ scavenging and a membrane-stabilizing action that limits the propagation of LP reactions between an LOO⅐ and an adjacent polyunsaturated fatty acid. The protective efficacy of tirilazad has been demonstrated in multiple animal models of acute TBI in mice, 41 rats, 42 and cats. 43 Although the compound is largely localized in the microvascular endothelium, the post-traumatic disruption of the BBB is known to allow the successful penetration of tirilazad into the brain parenchyma, as noted earlier. 44 Other mechanistic data derived from the ratcontrolled cortical impact and the mouse-diffused concussive head injury models have definitively shown that a major effect of tirilazad is to lessen post-traumatic BBB opening. 9, 44 Tirilazad was taken into clinical development in the early 1990s, and after a small phase II dose-escalation study that demonstrated the safety of the drug in TBI patients, tirilazad was evaluated in two phase III multicenter clinical trials for its ability to improve neurological recovery in moderately and severely injured closed TBI patients. One trial was conducted in North America and the other was in Europe. In both trials, TBI patients were treated within 4 h after injury with either vehicle or tirilazad (2.5 mg/kg intravenously every 6 h for 5 days). The North American trial was never published due to a major confounding imbalance in the randomization of the patients to a placebo or the tirilazad in regard to injury severity and pre-treatment neurological status. In contrast, the European trial had much better randomization balance and has been published. 30 The results failed to show a significant beneficial effect of tirilazad in either moderate (GCS ϭ 9 -12) or severe (GCS ϭ 4 -8) patient categories. However, a post hoc analysis showed that moderately-injured male TBI patients with traumatic SAH has significantly less mortality after treatment with tirilazad (6%) as compared with a placebo (24%; p Ͻ 0.026). In severely injured males with tSAH (tSAH), tirilazad also lessened mortality from 43% in placebo treated to 34% (p Ͻ 0.071). 30, 45 This result is consistent with the fact that this compound is also highly effective in animal models of SAH. 7 Nevertheless, additional trials would have been required to establish the neuroprotective usefulness of tirilazad in certain human TBI subgroups and to gain Food and Drug Administration approval in the United States. However, the sponsoring company Pharmacia & Upjohn opted not to continue the development of the compound for TBI, although it was successfully approved and marketed for use in aneurysmal SAH in several western European and Aus-tralian countries based on its demonstrated efficacy in phase III SAH trials.
46,47
Effects of direct and indirect-acting lipid peroxidation inhibitors
In addition to tirilazad, several other LP inhibitors have been reported to be effective neuroprotectants in TBI models. These include the lipid peroxyl radical (LOO⅐) scavenging 2-methylaminochromans U-78517F and U-83836E, 48 the pyrrolopyrimidine U-101033E, 48, 49 OPC-14117, 50 and the naturally-occurring LOO⅐ scavengers curcumin, 51, 52 and resveratrol, 53,54 the indoleamine melatonin, 21, [55] [56] [57] [58] and last, the endogenous antioxidant lipoic acid (FIG. 3) . 59 In the case of curcumin and resveratrol, these are potent LOO⅐ scavengers due to their possession of multiple phenolic hydroxyl groups that can donate electrons to LOO⅐ radicals. Melatonin also has LOO⅐ scavenging capability, 60 but in addition appears to react with PN. 61, 62 Lipoic acid may also have LOO⅐ scavenging effects, but these are more likely to be indirect via the regeneration (i.e., re-reduction) of other endogenous electron-donating antioxidants, including Vit E, glutathione, and Vit C.
Among these LP inhibitors, the most potent and effective LOO⅐ scavenging LP inhibitors yet discovered is the 2-methylaminochroman compound U-83836E which combines the LOO⅐ scavenging antioxidant chroman ring structure of Vit E with the bis-pyrrolopyrimidine moiety of tirilazad. The phenolic chroman antioxidant moiety can be re-reduced by endogenous ascorbic acid (Vit C) or glutathione after it has donated its phenolic electron to an initial LOO⅐ making it able to quench a second and then a third LOO⅐, and so on. The bis-pyrrolopyrimidine moiety, on the other hand, can also scavenge multiple moles of LOO⅐, but by a true catalytic mechanism. 49, 63 Thus, U-83836E, is a dual functionality LOO⅐ scavenger that is understandably more effective than either Vit E, tirilazad, 63 and possibly the other naturally-occurring LOO⅐ scavengers, such as curcumin, resveratrol, melatonin, and lipoic acid. Furthermore, U-83836E possesses a high degree of lipophilicity endowing it with a high affinity for membrane phospholipids in which LP takes place. Recent studies from the authors' laboratory in the mouse-controlled cortical impact TBI model have shown that U-83836E is able to reduce post-traumatic LP and protein nitration, and preserve mitochondrial respiratory function in injured cortical tissue and mitochondria. 64 
Nitroxide antioxidants and peroxynitrite scavengers
In addition to the lipid peroxyl (LOO⅐) radical scavengers, the neuroprotective effects of a family of nitroxide-containing antioxidants have also been examined in experimental TBI models. These are sometimes referred to as "spin-trapping agents," and include ␣-phenyl-tertbutyl nitrone and its thiol analog NXY-059 and tempol (see bottom of FIG. 3) . Both alpha-phenyl-tert-butyl nitrone and tempol have been shown to be protective in rodent TBI paradigms. 65, 66 As mentioned earlier, tempol has been shown by the author and colleagues to catalytically scavenge PN-derived ⅐NO 2 and ⅐CO 3 , 28, 67 and to reduce post-traumatic oxidative damage (both LP and protein nitration), preserve mitochondrial function, decrease calcium-activated, calpain-mediated cytoskeletal damage, and reduce neurodegeneration in mice subjected to a severe controlled cortical impact-induced focal TBI. 68 Another laboratory has reported that tempol can reduce post-traumatic brain edema and improve neurological recovery in the rat contusion injury model. 69, 70 However, the neuroprotective effect of tempol administered alone is associated with a therapeutic window of an hour or less in the mouse-controlled cortical impact TBI model. Moreover, tempol is not effective at directly inhibiting LP in the latter model.
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Effects of the iron chelator deferoxamine
The prototype iron chelator deferoxamine that binds ferric (Fe ϩϩϩ ) iron, and thereby would lessen the catalytic effects of iron on LP, has also been reported to have beneficial actions in preclinical TBI or TBI-related models. 71, 72 However, deferoxamine is hindered by its lack of brain penetration and rapid plasma elimination rate. To partially counter the latter limitation, a dextran-coupled deferoxamine has been synthesized that has been reported to significantly improve early neurological recovery in a mouse diffuse TBI model. 73 Much of this activity, however, is probably due to microvascular antioxidant protection because of limited brain penetrability. Another caveat to the iron-chelation antioxidant neuroprotective approach that is at least relevant to the ferric iron chelators, such as deferoxamine, is that they can cause a pro-oxidant effect in that their binding of Fe ϩϩϩ can actually drive the oxidation of ferrous to ferric iron, which can increase superoxide radical formation in the process (Fe
.
Carbonyl scavenging as an approach to inhibit 4-HNE and acrolein binding to proteins
As pointed out earlier (FIG. 2) , the LP-derived aldehydic (carbonyl-containing) breakdown products 4-HNE and acrolein have a high affinity for binding to selected protein amino acid residues including histidine, lysine, arginine, and cysteine. These modifications have been shown to inhibit the activities of a variety of enzymatic proteins. 3 Several compounds have been recently identified that are able to antagonize this "carbonyl stress" by covalently binding to reactive LP-derived aldehydes. For instance, D-penicillamine has been demonstrated to form an irreversible bond to primary aldehydes. We have previously demonstrated that penicillamine is able to scavenge PN 74 and to protect brain mitochondria from PNinduced respiratory dysfunction in isolated rat brain mitochondria. 75 This latter action was observed along with an attenuation of 4-HNE-modified mitochondrial proteins. 75 The PN scavenging action of penicillamine, along with its carbonyl scavenging capability may jointly explain our previous findings that acutely administered penicillamine can improve early neurological recovery of mice subjected to moderately severe concussive TBI. 76 More recently, it has been demonstrated that a variety of hydrazine (-NH-NH 2 )-containing compounds such as the anti-hypertensive agent hydralazine, the anti-depressant phenelzine, and the anti-tubercular agent iproniazid can react with the carbonyl moieties of 4-HNE or acrolein, which prevents the latter from binding to susceptible amino acids in proteins. 77 Consistent with this effect being neuroprotective, others have shown that hydralazine inhibits either compression or acrolein-mediated injuries to ex vivo spinal cord. 78 Hydralazine, which is a potent vasodilator would be difficult to administer in vivo after either spinal cord injury or TBI, in which hypotension is already a common pathophysiological problem. However, other hydrazine-containing compounds, such as phenelzine and iproniazid, do not compromise blood pressure as readily as hydralazine, and have a long history of clinical use, although never having been examined in acute neurotrauma models. Most impressive is the fact that the application of hydrazines can rescue cultured cells from 4-HNE toxicity, even when administered after the 4-HNE has already covalently bound to cellular proteins. 77 Such an effect could be associated with a favorable neuroprotective therapeutic window.
RATIONALE FOR COMBINATION ANTIOXIDANT TREATMENT OF TBI
Antioxidant neuroprotective therapeutic discovery directed at acute TBI has consistently been focused on attempting to inhibit the secondary injury cascade by pharmacological targeting of a single oxidative damage mechanism. As presented previously, these efforts have included either enzymatic scavenging of superoxide radicals with SOD 34 or inhibition of LP with tirilazad. 30 Although each of these strategies has shown protective efficacy in animal models of TBI, phase III clinical trials with either compound failed to demonstrate a statistically significant positive effect, although the post hoc subgroup analysis suggests that the microvascularly localized tirilazad may have efficacy in moderate and severe TBI patients with tSAH. 30 Although there are many reasons that have been identified as possible contributors to the failure, one logical explanation has to with the possible need to interfere at multiple points in the oxidative damage portion of the secondary injury cascade, either simultaneously or in a phased manner, to achieve a clinically demonstrable level of neuroprotection.
In addition to the antioxidant strategy of scavenging the initiating radicals and stopping the propagation of LP reactions in the injured brain tissue, recent work has shown that carbonyl scavenging compounds can also act to protect cellular proteins from the binding of neurotoxic LP-derived aldehydes. Thus, we are presently exploring the neuroprotective efficacy of three of the prototypes of this new class of compound alone and in combination with the PN-radical scavenging tempol and/or the LP-inhibiting U-83836E . FIG. 4 summarizes the overall rationale for a multi-mechanistic antioxidant therapy for TBI. It is anticipated that the combination of two or three antioxidant mechanistic strategies may improve the extent of neuroprotective efficacy, lessen the variability of the effect, and possibly provide a longer therapeutic window of opportunity compared with the window for the individual strategies. If these theoretical combinatorial benefits are confirmed in preclinical TBI models, then this should greatly enhance the chance of neuroprotective success in future clinical trials in contrast to previous failures with single antioxidant agents. ⅐Ϫ and NO⅐ combine to form the potent reactive nitrogen species PN, which is able to in turn give rise to the highly reactive nitrogen dioxide (⅐NO 2 ), hydroxyl (⅐OH), and carbonate (⅐CO 3 ) radicals that cause oxidative damage to the mitochondria, as well as other cellular structures due to PNs large diffusion radius. When this becomes severe, there is a decrease in the mitochondrial ATP production and membrane potential (⌬⌿). This leads to catastrophic mitochondrial failure (mitochondrial permeability transition [MPT] ) and the dumping of mitochondrial Ca ϩϩ into the cytoplasm where it exacerbates cytoplasmic calpain activation and proteolysis of a cytoskeletal proteins and other substrates. The combination of the antioxidant tempol, which catalytically reacts with PN-derived radicals with a chain-breaking lipid peroxidation (LP) inhibitor such as U-83836E or a carbonyl (CHO) scavenging compound that should produce a better neuroprotective effect than any of these compounds alone.
